Cuatrecasas advised Arcline Investment Management on the deal.Arcline Investment Management (“Arcline”), a growth-oriented private equity firm with $4.3 billion of cumulative capital commitments, executed the acquisition of Polypeptide Therapeutic…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
